EFFECT OF TRIMETAZIDINE IN A ROSUVASTATIN-BISOPROLOL COMBINATION ON BLOOD LEVELS OF C-REACTIVE PROTEIN AND GLUCOSE IN PATIENTS WITH CORONARY HEART DISEASE


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

This controlled pilot study showed that just 2 weeks after therapy with bisoprolol and rozuvastatine, the trimetazidine (Predizine)-treated patients with stable angina pectoris without diabetes mellitus had lower blood glucose and C-reactive protein levels and fewer angina attacks and needed less additional use of nitroglycerin and amlodipine.

全文:

受限制的访问

参考

  1. Onay-Besikci A., Özkan S. Trimetazidine Revisited: A Comprehensive Review of the Pharmacological Effects and Analytical Techniques for the Determination of Trimetazidine // Cardiovasc. Ther. - 2008; 26 (2): 147-65
  2. Национальные рекомендации по диагностике и лечению стабильной стенокардии ВНОК // Кардиоваск. тер. и профилакт. - 2008; 7 (6, прил. 4).
  3. Kutala V., Khan M., Mandal R. et al. Attenuation of Myocardial Ischemia-Reperfusion Injury by Trimetazidine Derivatives Functionalized with Antioxidant Properties // J. Pharmacol. Exp. Ther. - 2006; 317: 921-8.
  4. Kantor P., Lucien A., Kozak R. et al. The Antianginal Drug Trimetazidine Shifts Cardiac Energy Metabolism From Fatty Acid Oxidation to Glucose Oxidation by Inhibiting Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase // Circ. Res. - 2000; 86: 580-8.
  5. Jayle C. et al. Comparison of protective effects of trimetazidine against experimental warm ischemia of different durations: early and long-term effects in a pig kidney model // Am. J. Physiol. Renal Physiol. - 2007; 292: 1082-93.
  6. Liu X. et al. Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway // Cardiovasc. Res. - 2010; 88: 150-8.
  7. Preiss D., Seshasai S., Welsh P. et al. Risk of incident diabetes with intensive dose compared with moderate-dose statin therapy // JAMA. - 2011; 305: 2556-64.
  8. Шевченко А.О., Шевченко О.П. Бета-адреноблокаторы. От класс-эффекта к уникальности отдельных представлений // Врач. - 2010; 3: 62-5.
  9. Bucci M., Borra R., Någren K. et al. Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans // Cardiovasc. Ther. - 2012; 30 (6): 333-41.
  10. Monti L., Setola E., Fragasso G. et al. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy // Am. J. Physiol. Endocrinol. Metab. - 2006; 290: 54-9.
  11. Fragasso G., Piatti M. et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy // Am. Heart J. - 2003; 146: 18.
  12. Lithell H. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism // Diabetes Care. - 1991; 14: 203-9.
  13. Bakris G., Fonseca V., Katholi R. et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial // JAMA. - 2004; 292: 2227-36.
  14. Dominguez L. et al. Bisoprolol and captopril effects on insulin receptor kinase activity in essential hypertension // Am. J. Hypertens. - 1997; 10: 1349.
  15. Fogari R., Zoppi A., Pasotti C. et al. Plasma lipids during chronic antihypertensive therapy with different beta-blockers // J. Cardiovasc. Pharmacol. -1989; 14 (7): 28-32.
  16. Sattar N., Preiss D., Murray H. et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials // Lancet. - 2010; 375 (9716): 735-42.
  17. Ridker P. et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial // Lancet. - 2012; 380 (9841): 565-71.
  18. Шевченко О.П., Шевченко А.О. Статины. Ингибиторы ГМК-КоА-редуктазы / М.: Реафарм, 2003.
  19. Дворянкова Е.В., Шевченко А.О., Шевченко О.П. и др. Эффективность и безопасность симвастатина у больных распространенным псориазом // Дальневост. вестн. дерматовенерол., косметол. и пластич. хир. - 2010; 1 (7): 22-6.
  20. Napoli P., Taccardi A., Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy // Heart. - 2005; 91: 161-5.
  21. Kuralay F., Altekin E., Yazlar A. et al. Suppression of angioplasty-related inflammation by pre-procedural treatment with trimetazidine // Tohoku J. Exp. Med. -2006; 208: 203-12.
  22. Dogan A., Ozaydin M., Gedikli O. et al. Effect of trimetazidine on exercise performance in patients with coronary artery ectasia // Jpn Heart J. - 2003; 44: 463-70.
  23. Topal E., Ozdemir R., Barutcu I. et al. The effects of trimetazidine on heart rate variability in patients with slow coronary artery flow // J. Electrocardiol. - 2006; 39: 211-8.
  24. Di Napoli P., Chierchia S., Taccardi A. et al. Trimetazidine improves post-ischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts // Nitric. Oxide. - 2007; 16: 228-36.
  25. Tuunanen H. et al. Trimetazidine, a Metabolic Modulator, Has Cardiac and Extracardiac Benefits in Idiopathic Dilated Cardiomyopathy // Circulation. - 2008; 118: 1250-8.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2013